What class of compound is Cagrilintide?

Cagrilintide is classified as a Long-acting amylin analogue. Within this class, alternative names and analogues include AM833. The class-level pharmacology shapes both the clinical applications and the safety profile; the female physiology literature treats Cagrilintide alongside its class peers when evaluating relative merits.

How long until I see results from Cagrilintide?

Acute effects from Cagrilintide appear within the first week for downstream physiological adaptation. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What should I look for in Cagrilintide sourcing and quality?

Acceptable Cagrilintide certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~4400 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How does Cagrilintide's half-life affect dosing?

Cagrilintide has a plasma half-life of ~7 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at 1.2-2.4 mg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

What are the safety considerations for Cagrilintide?

Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. For female hormonal and cyclical use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Cagrilintide's ~7 days pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ Cagrilintide

Cagrilintide

Women's Health

For women considering Cagrilintide, the framework spans three life stages: reproductive, perimenopausal, and postmenopausal. Each carries distinct hormonal context and distinct monitoring requirements. A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone. The ~7 days pharmacokinetic profile shapes how the compound is felt across follicular versus luteal phases in pre-menopausal users and how it integrates with HRT in older cohorts.

Female Physiology Applications

Libido (Female)Vaginal HealthPCOS SupportCycle SupportBody Composition (Female)

Key Takeaways

Female-physiology lens: Cagrilintide response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex).
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 1.2-2.4 mg 1x weekly subq via subq; cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. Female-physiology implications operate across three life-stage contexts: pre-menopausal cyclical users, the perimenopausal transition, and post-menopausal users on or off HRT. Cagrilintide's response varies meaningfully across these contexts, as the subsections on cyclical context, perimenopause integration, fertility, and bone-and-cardiovascular signalling describe.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and Cagrilintide's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Cagrilintide's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Fertility and reproductive considerations

Cagrilintide's effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Body Composition (Female)

In the perimenopausal window, Cagrilintide for body composition (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Fertility

For fertility in female users, Cagrilintide is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Libido (Female)

Libido (Female) is one of the dimensions on which women track Cagrilintide response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Hair Health

In the perimenopausal window, Cagrilintide for hair health produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1.2-2.4 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.2-2.4 mg	4–6 weeks initial cycle
Women's Health focus	SubQ	1.2-2.4 mg	1x weekly SubQ
Maintenance phase	SubQ	1.2-2.4 mg	Ongoing with periodic pauses

Dose timing for Cagrilintide is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Cagrilintide stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Cagrilintide + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Cagrilintide's mechanism in female physiology protocols.
Cagrilintide + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Cagrilintide's mechanism in female physiology protocols.
Cagrilintide + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Cagrilintide's mechanism in female physiology protocols.
Cagrilintide + Epithalon: Identified by Khavinson in St. Pairs naturally with Cagrilintide's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Investigational (Phase III combined with semaglutide as CagriSema) Research: Phase III trials underway

Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy.

Lens-specific safety considerations for female physiology use of Cagrilintide: Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Once-weekly cagrilintide for weight management in people with overweight and obesity

PMID 34861246

Supporting

CagriSema (cagrilintide + semaglutide) in type 2 diabetes

PMID 37271482

Cagrilintide vs Related Peptides

Compound	Profile	Onset	Best For
Cagrilintide	Long-acting amylin analogue	~7 days	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Is Cagrilintide appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

How will Cagrilintide interact with my cycle?

For pre-menopausal users, response to Cagrilintide often varies across follicular and luteal phases. The first 1–2 cycles should be used to track response by phase before settling on a fixed schedule. Even where the compound's pharmacology is not directly cyclical, metabolism and felt response shift across the cycle.

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Does Cagrilintide affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where Cagrilintide specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

How should Cagrilintide be stored and reconstituted?

Lyophilised Cagrilintide stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Is Cagrilintide safe during pregnancy or breastfeeding?

Cagrilintide, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Clinical Protocol

Start a Cagrilintide Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Cagrilintide and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: ~4400 Da
Sequence length: 37 aa
Half-life: ~7 days
WADA: Not on prohibited list
FDA: Investigational (Phase III combined with semaglutide as CagriSema)
Research: Phase III trials underway

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Cagrilintide unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Cagrilintide

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised